apg-1387
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 12, 2017 (NCT03386526)
Timeline
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594459 ↗
Also known as
- apg-1387
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04643405 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2020 | Ascentage Pharma Group Inc. |
| NCT04568265 | Phase 2 | Jun 3, 2020 | Ascentage Pharma Group Inc. |
| NCT04354727 | Phase 1/Phase 2 (Phase 2) | May 30, 2020 | Ascentage Pharma Group Inc. |
| NCT04284488 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2020 | Ascentage Pharma Group Inc. |
| NCT03585322 | Phase 1 | Jul 4, 2018 | Ascentage Pharma Group Inc. |
| NCT03386526 | Phase 1/Phase 2 (Phase 2) | Dec 12, 2017 | Ascentage Pharma Group Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascentage Pharma Group Inc. | For profit | 6 | 6 | 2 | 2017 |
1 organizations
Page 1 / 1